Overview

Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

A Phase II, interventional study of neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy, followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with borderline resectable stage III Non-small Cell Lung Cancer (NSCLC) (ACCESS)

Phase:

PHASE2

Details

Lead Sponsor:

Bi Nan

Collaborator:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Treatments:

Chemoradiotherapy
durvalumab
Surgical Procedures, Operative